Use Sativex as an adjunct
when patients’ first-line oral
anti-spasticity medications
are not enough1–3

Contraindications
Image
icons

Sativex has limited
contraindications and
requirements for dose
adjustments1

 

 

Contraindications

 

 

Patients with hypersensitivity to cannabinoids or to any of the excipients1

 

Patients with any known or suspected history or family history of schizophrenia, or other psychotic illness; history of severe personality disorder or other significant psychiatric disorder other than depression associated with their underlying condition1

 

Patients who are breastfeeding1

 

 

Patients with significant hepatic or renal impairment

 

 

Sativex can be administered to patients with mild hepatic impairment without any dose adjustment1

– Administration to patients with moderate or severe hepatic impairment is not advised due to the lack of information on the potential for accumulation of THC and CBD with chronic dosing1

 

The effects of Sativex may be exaggerated or prolonged in patients with impaired renal function. Frequent clinical evaluation by a clinician is recommended in these patients1

 

 

Elderly patients

 

No specific studies have been carried out in elderly patients, although patients up to 90 years of age have been included in clinical trials1

 

As elderly patients may be more prone to develop some CNS adverse reactions, care should be taken in terms of personal safety such as preparation of hot food and drinks1